renal cell carcinomatyrosine kinase inhibitorsmTOR inhibitorseverolimusoverall and relapse-free survivaleffectivenessпочечно-клеточный ракингибиторы тирозинкиназыингибиторы mTORэверолимусобщая и безрецидивная выживаемостьэффективность1.1. Cohen H., McGovern F. Renal cell carcinoma. N Engl J Med 2005;353:3477–90.Cohen H., McGovern F. Renal cell carcinoma. N Engl J Med 2005;353:3477–90.2.2. American Cancer Society, Cancer Facts & Figures 2008. http://www.cancer.org/docroot/STT/content/STT_1x_Cancer_Facts_and_Figures_2008.aspAmerican Cancer Society, Cancer Facts & Figures 2008. http://www.cancer.org/docroot/STT/content/STT_1x_Cancer_Facts_and_Figures_2008.asp3.3. Surveillance, Epidemiology and End Results (SEER). Cancer Stat Fact Sheets. http://www.seer.cancer.gov/statfacts/index.htmlSurveillance, Epidemiology and End Results (SEER). Cancer Stat Fact Sheets. http://www.seer.cancer.gov/statfacts/index.html4.4. Parkin D.M., Bray F., Ferlay J., Pisani P.Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74–108.Parkin D.M., Bray F., Ferlay J., Pisani P.Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74–108.5.5. Чиссов В.И., Старинский В.В., Петрова Г.В. Злокачественные новообразования в России в 2008 году. М., 2010.Чиссов В.И., Старинский В.В., Петрова Г.В. Злокачественные новообразования в России в 2008 году. М., 2010.6.6. Flanigan R.C., Mickisch G., Sylvester R. et al. Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis.J Urol 2004;171:1071–6.Flanigan R.C., Mickisch G., Sylvester R. et al. Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis.J Urol 2004;171:1071–6.7.7. Coppin C., Porzsolt F., Autenrieth M. et al. Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev 2004; 3: CD001425.Coppin C., Porzsolt F., Autenrieth M. et al. Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev 2004; 3: CD001425.8.8. Motzer R.J., Bander N.H.,Nanus D.M. Renal cell carcinoma. N Engl J Med 1996;335:865–75.Motzer R.J., Bander N.H.,Nanus D.M. Renal cell carcinoma. N Engl J Med 1996;335:865–75.9.9. Ljungberg B., Hanbury D.C., Kuczyk M.A. et al. Guidelines on renal cell cancer. European Association of Urology, 2009.Ljungberg B., Hanbury D.C., Kuczyk M.A. et al. Guidelines on renal cell cancer. European Association of Urology, 2009.10.10. Yagoda A., Abi-Rached B., Petrylak D. Chemotherapy for advanced renal-cell carcinoma: 1983–1993. Semin Oncol 1995;22:42–60.Yagoda A., Abi-Rached B., Petrylak D. Chemotherapy for advanced renal-cell carcinoma: 1983–1993. Semin Oncol 1995;22:42–60.11.11. Patard J.-J. New treatment options for renal cell cancer – critical evaluation. Eur Urol 2008;(Suppl 7): 443–6.Patard J.-J. New treatment options for renal cell cancer – critical evaluation. Eur Urol 2008;(Suppl 7): 443–6.12.12. Motzer R.J., Hutson T.E., Tomczak P. et al. Sunitinib versus interferon alfa in metastatic renal-cell arcinoma. N Engl J Med 2007;356:115–24.Motzer R.J., Hutson T.E., Tomczak P. et al. Sunitinib versus interferon alfa in metastatic renal-cell arcinoma. N Engl J Med 2007;356:115–24.13.13. Escudier B., Eisen T., Stadler W. et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356:125–34.Escudier B., Eisen T., Stadler W. et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356:125–34.14.14. Hudes G., Carducci M., Tomczak P. et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007;356:2271–81.Hudes G., Carducci M., Tomczak P. et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007;356:2271–81.15.15. Motzer R.J., Escudier B., Oudard S. et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008;372:449–56.Motzer R.J., Escudier B., Oudard S. et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008;372:449–56.16.16. Oudard S., Medioni J., Aylllon J. et al. Everolimus (RAD001): an mTOR inhibitor for the treatment of metastatic renal cell carcinoma. Expert Rev Anticancer Ther 2009; 9(6):705–17.Oudard S., Medioni J., Aylllon J. et al. Everolimus (RAD001): an mTOR inhibitor for the treatment of metastatic renal cell carcinoma. Expert Rev Anticancer Ther 2009; 9(6):705–17.17.17. Kaelin W.G. The von Hippel–Lindau tumor suppressor gene and kidney cancer. Clin Cancer Res 2004;10:6290–5.Kaelin W.G. The von Hippel–Lindau tumor suppressor gene and kidney cancer. Clin Cancer Res 2004;10:6290–5.18.18. Трапезникова М.Ф., Глыбин П.А., Морозов А.П. и др. Ангиогенные факторы при почечно-клеточном раке. Онкоурология 2008;(4):82–7.Трапезникова М.Ф., Глыбин П.А., Морозов А.П. и др. Ангиогенные факторы при почечно-клеточном раке. Онкоурология 2008;(4):82–7.19.19. Larkin J.M.G., Kipps E.L.S., Powell C.J.,Swanton C. Review: systemic therapy for advanced renal cell carcinoma. Ther Advanc Med Oncol 2009;1:15–27.Larkin J.M.G., Kipps E.L.S., Powell C.J.,Swanton C. Review: systemic therapy for advanced renal cell carcinoma. Ther Advanc Med Oncol 2009;1:15–27.20.20. Ravaud A., Wallerand H., Culine S. et al. Update on the medical treatment of metastatic renal cell carcinoma. Eur Urol 2008;54(2):315–25.Ravaud A., Wallerand H., Culine S. et al. Update on the medical treatment of metastatic renal cell carcinoma. Eur Urol 2008;54(2):315–25.21.21. Hay N., Sonenberg N. Upstream and downstream of mTOR. Genes Dev 2004;18:1926–45.Hay N., Sonenberg N. Upstream and downstream of mTOR. Genes Dev 2004;18:1926–45.22.22. Abraham R.T., Gibbons J.J. The mammalian target of rapamycin signaling pathway: twists and turns in the road to cancer therapy. Clin Cancer Res 2007;13:3109–14.Abraham R.T., Gibbons J.J. The mammalian target of rapamycin signaling pathway: twists and turns in the road to cancer therapy. Clin Cancer Res 2007;13:3109–14.23.23. Seelinger H., Guba M., Kleespies A. et al. Role of mTOR in solid tumour systems: a therapeutical target against primary tumour growth, metastases, and angiogenesis. Cancer Metastasis Rev 2007;26(3–4):611–21.Seelinger H., Guba M., Kleespies A. et al. Role of mTOR in solid tumour systems: a therapeutical target against primary tumour growth, metastases, and angiogenesis. Cancer Metastasis Rev 2007;26(3–4):611–21.24.24. Cho D., Signoretti S., Regan M. et al. The role of mammalian target of rapamycin inhibitors in the treatment of advanced renal cancer. Clin Cancer Res 2007;13(2 Suppl):758–63.Cho D., Signoretti S., Regan M. et al. The role of mammalian target of rapamycin inhibitors in the treatment of advanced renal cancer. Clin Cancer Res 2007;13(2 Suppl):758–63.25.25. Hudson C.C., Liu M., Chiang G.G. et al. Regulation of hypoxia-inducible factor 1 alpha expression and function by the mammalian target of rapamycin. Mol Cell Biol 2002;22:7004–14.Hudson C.C., Liu M., Chiang G.G. et al. Regulation of hypoxia-inducible factor 1 alpha expression and function by the mammalian target of rapamycin. Mol Cell Biol 2002;22:7004–14.26.26. Pantuck A.J., Seligson D.B., Klatte T. et al. Prognostic relevance of the mTOR pathway in renal cell carcinoma: implications for molecular patient selection for targeted therapy. Cancer 2007;109:2257–67.Pantuck A.J., Seligson D.B., Klatte T. et al. Prognostic relevance of the mTOR pathway in renal cell carcinoma: implications for molecular patient selection for targeted therapy. Cancer 2007;109:2257–67.27.27. Pascual J. Everolimus in clinical practice-renal transplantation. Nephrol Dial Transplant 2006;21(Suppl 3):18–23.Pascual J. Everolimus in clinical practice-renal transplantation. Nephrol Dial Transplant 2006;21(Suppl 3):18–23.28.28. Tabernero J., Rojo F., Calvo E. et al. Doseand schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors. J Clin Oncol 2008;26(10):1603–10.Tabernero J., Rojo F., Calvo E. et al. Doseand schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors. J Clin Oncol 2008;26(10):1603–10.29.29. O'Donnell A., Faivre S., Burris H.A. III et al. Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors. J Clin Oncol 2008;26(10):1588–95.O'Donnell A., Faivre S., Burris H.A. III et al. Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors. J Clin Oncol 2008;26(10):1588–95.30.30. Tanaka C., O’Reilly T., Kovarik J.M. et al. Identifying optimal biologic doses of everolimus (RAD001) in patients with cancer based on the modeling of preclinical and clinical pharmacokinetic and pharmacodynamic data. J Clin Oncol 2008;26(10):1596–602.Tanaka C., O’Reilly T., Kovarik J.M. et al. Identifying optimal biologic doses of everolimus (RAD001) in patients with cancer based on the modeling of preclinical and clinical pharmacokinetic and pharmacodynamic data. J Clin Oncol 2008;26(10):1596–602.31.31. Jac J., Giessinger S., Khan M. et al. A phase II trial of RAD001 in patients (pts) with metastatic renal cell carcinoma (MRCC). 2007ASCO Annual Meeting Proceedings. J Clin Oncol 2007;25:5107.Jac J., Giessinger S., Khan M. et al. A phase II trial of RAD001 in patients (pts) with metastatic renal cell carcinoma (MRCC). 2007ASCO Annual Meeting Proceedings. J Clin Oncol 2007;25:5107.32.32. Jac J., Amato R.J., Giessinger S. et al. A phase II study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic renal cell carcinoma which has progressed on tyrosine kinase inhibition therapy. 2008 ASCO Annual Meeting Proceedings. J Clin Oncol 2008;26:5113.Jac J., Amato R.J., Giessinger S. et al. A phase II study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic renal cell carcinoma which has progressed on tyrosine kinase inhibition therapy. 2008 ASCO Annual Meeting Proceedings. J Clin Oncol 2008;26:5113.33.33. Whorf R.C., Hainsworth J.D., Spigel D.R. et al. Phase II study of bevacizumab and everolimus (RAD001) in the treatment of advanced renal cell carcinoma (RCC). J Clin Oncol 2008;26:5010.Whorf R.C., Hainsworth J.D., Spigel D.R. et al. Phase II study of bevacizumab and everolimus (RAD001) in the treatment of advanced renal cell carcinoma (RCC). J Clin Oncol 2008;26:5010.34.34. Motzer R.J., Escudier B., Oudard S. et al. Efficacy of everolimus in advanced renal cell carcinoma: A double-blind, randomised, placebo-controlled phase III trial. Lancet 2008;372:449–56.Motzer R.J., Escudier B., Oudard S. et al. Efficacy of everolimus in advanced renal cell carcinoma: A double-blind, randomised, placebo-controlled phase III trial. Lancet 2008;372:449–56.35.35. Escudier B., Ravaud A., Oudard S. et al. Phase-3 randomized trial of everolimus (RAD001) vs placebo in metastatic renal cell carcinoma [Abstr 720]. Ann Oncol 2008;19:45.Escudier B., Ravaud A., Oudard S. et al. Phase-3 randomized trial of everolimus (RAD001) vs placebo in metastatic renal cell carcinoma [Abstr 720]. Ann Oncol 2008;19:45.36.36. Motzer R.J., Kay A., Figlin R. et al. Updated data from a phase III randomized trial of everolimus (RAD001) versus PBO in metastatic renal cell carcinoma (mRCC). ASCO 2009 Genitourinary Cancers Symposium [Abstr 278]. American Society of Clinical Oncology web site. http://www.asco.org/ASCOv2/MultiMedia/Virtual+Meeting?&vmview=vm_session_presentations_view&confID=64sessionID=11Motzer R.J., Kay A., Figlin R. et al. Updated data from a phase III randomized trial of everolimus (RAD001) versus PBO in metastatic renal cell carcinoma (mRCC). ASCO 2009 Genitourinary Cancers Symposium [Abstr 278]. American Society of Clinical Oncology web site. http://www.asco.org/ASCOv2/MultiMedia/Virtual+Meeting?&vmview=vm_session_presentations_view&confID=64sessionID=1137.37. Ravaud A., Wallerand H. Molecular pathways in metastatic renal cell carcinoma: the evolving role of mammalian target of rapamycin inhibitors. Eur Urol Suppl 2009;8:793–8.Ravaud A., Wallerand H. Molecular pathways in metastatic renal cell carcinoma: the evolving role of mammalian target of rapamycin inhibitors. Eur Urol Suppl 2009;8:793–8.38.38. Ljungberg B., Hanbury D.C., Kuczyk M.A.et al. Guidelines on renal cell carcinoma. European Association of Urology web site. http://www.uroweb.org/fileadmin/tx_eauguidelines/2009/Full/RCC.pdfLjungberg B., Hanbury D.C., Kuczyk M.A.et al. Guidelines on renal cell carcinoma. European Association of Urology web site. http://www.uroweb.org/fileadmin/tx_eauguidelines/2009/Full/RCC.pdf39.39. Escudier B., Kataja V. Renal cell carcinoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol2009;20(Suppl 4):81–2.Escudier B., Kataja V. Renal cell carcinoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol2009;20(Suppl 4):81–2.40.40. De Reijke T.M., Bellmunt J., van Poppel H. et al. EORTC-GU group expert opinion on metastatic renal cell cancer. Eur J Cancer 2009;45:765–73.De Reijke T.M., Bellmunt J., van Poppel H. et al. EORTC-GU group expert opinion on metastatic renal cell cancer. Eur J Cancer 2009;45:765–73.41.41. NCCN clinical practice guidelines in oncology: kidney cancer. National Comprehensive Cancer Network web site.http://www.nccn.org/professionals/physician_gls/f_guidelines.aspNCCN clinical practice guidelines in oncology: kidney cancer. National Comprehensive Cancer Network web site.http://www.nccn.org/professionals/physician_gls/f_guidelines.asp42.42. Rosenberg J.E., Weinberg V.K., Claros C. et al. Phase I study of sorafenib and RAD001 for metastatic clear cell renal cell carcinoma. J Clin Oncol 2008;26(Suppl):abstr 5109.Rosenberg J.E., Weinberg V.K., Claros C. et al. Phase I study of sorafenib and RAD001 for metastatic clear cell renal cell carcinoma. J Clin Oncol 2008;26(Suppl):abstr 5109.43.43. Yuan R., Kay A., Berg W.J., Lebwohl D. Targeting tumorigenesis: development and use of mTOR inhibitors in cancer therapy. J Hematol Oncol 2009;2:45.Yuan R., Kay A., Berg W.J., Lebwohl D. Targeting tumorigenesis: development and use of mTOR inhibitors in cancer therapy. J Hematol Oncol 2009;2:45.44.44. NCT00719264: Safety and efficacy of bevacizumab plus RAD001 versus interferon alfa 2a and bevacizumab in adult patients with kidney cancer (L2201). http://www.clinicaltrials.govNCT00719264: Safety and efficacy of bevacizumab plus RAD001 versus interferon alfa 2a and bevacizumab in adult patients with kidney cancer (L2201). http://www.clinicaltrials.gov45.45. NCT00903175: Efficacy and safety comparison of RAD001 versus sunitinib in the first-line and second-line treatment of patients with metastatic renal cell carcinoma(RECORD-3). http://www.clinicaltrials.govNCT00903175: Efficacy and safety comparison of RAD001 versus sunitinib in the first-line and second-line treatment of patients with metastatic renal cell carcinoma(RECORD-3). http://www.clinicaltrials.gov